titulo-menu-Alzheimer

Enviado por admin el Lun, 26/01/2009 - 11:18.

Artículos recomendados

  • Physiological Reviews

    Volumen 8, Número 2, Páginas 361-385; Abril, 2004

    Role of Tau Protein in Both Physiological and Pathological Conditions

    Jesús Avila, José J. Lucas, Mar Pérez, and Félix Hernández.

    Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Facultad de Ciencias, Campus de Cantoblanco, Madrid, Spain

  • Neurobiology of Aging

    Volumen 28, Número 10, Páginas 1465-1636; Octubre, 2007

    Is aging part of Alzheimer’s disease, or is Alzheimer’s disease part of aging?

    Russell H. Swerdlow

    Department of Neurology, University of Virginia Health System, McKim Hall, 1 Hospital Drive, P.O. Box 800394, Charlottesville, VA 22908, United States

  • Neurobiology of Aging

    Volumen 25, Número 3, Páginas 273-416; Marzo, 2004

    Neurochemical diagnosis of Alzheimer’s dementia by CSF A42, A42/A40 ratio and total tau

    Piotr Lewczuk a, Hermann Esselmann b , Markus Otto b , Juan Manuel Maler a , Andreas Wolfram Henkel a , Maria Kerstin Henkel a , Oliver Eikenberg c , Christof Antz c , Wolf-Rainer Krause d , Udo Reulbach e , Johannes Kornhuber, Jens Wiltfang a.

    a Molecular Neurobiology Lab, Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany.
    b Department of Psychiatry, University of Goettingen, von-Siebold-Str. 5, 37075 Goettingen, Germany.
    c ABETA GmbH, Im Neuenheimer Feld 584, 69120 Heidelberg, Germany.
    d Department of Psychiatry and Psychotherapy, Thiestr. 7-10, 38889 Blankenburg, Germany.
    e Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nuremberg, Waldstr. 6, 91054 Erlangen, Germany.

  • Nature Reviews / NEUROSCIENCE

    Volumen 9, Número 10, Páginas 768-778; Octubre, 2008 

    Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses.

    Lars Bertram and Rudolph E. Tanzi

    Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, Massachusetts 02129, USA.

  • ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY

    Volumen 43, Páginas 545-584; Abril, 2003

    ALZHEIMER’S DISEASE: Molecular Understanding Predicts Amyloid-Based Therapeutics

    Dennis J. Selkoe¹ and Dale Schenk²

    ¹Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts 02115 ²Elan Pharmaceuticals, South San Francisco, California 94080

  • TRENDS in Molecular Medicine

    Volumen 11, Número 4, Páginas 145-197; Abril, 2005

    Tau phosphorylation in Alzheimer’s disease: pathogen or protector?

    Hyoung-gon Lee1, George Perry1, Paula I. Moreira 1,2, Matthew R. Garrett1, Quan Liu1, Xiongwei Zhu1, Atsushi Takeda3, Akihiko Nunomura4 and Mark A. Smith1

    1Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106 USA.
    2Center for Neuroscience and Cell Biology of Coimbra, University of Coimbra, 3004-517 Coimbra, Portugal .
    3Department of Neurology, Tohoku University School of Medicine, Sendai, Miyagi 980-8574, Japan .
    4Department of Psychiatry and Neurology, Asahikawa Medical College, Asahikawa 078-8510, Japan .

  • La Enfermedad de Alzheimer

    Manuel Sarasa

    Director Científico de Araclon Biotech, Zaragoza, España.

    Descargar PDF

  • PHYSIOLOGICAL REVIEWS

    Volumen 81, Número 2, Páginas 741-766; Abril, 2001

    Alzheimer’s Disease: Genes, Proteins, and Therapy.

    Dennis J. Selkoe

    Department of Neurology and Program in Neuroscience, Harvard Medical School, and Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, Massachusetts.

    Descargar PDF